Related Experiment Video

Updated: Jan 16, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.5K

Two Cases of Heterozygous Familial Hypercholesterolemia in Children Effectively Managed With Pitavastatin and

Katsufumi Nishioka1, Sonoko Kondo1, Kanako Irie1

  • 1Department of Pediatrics, Faculty of Medicine Kagawa University Miki Kagawa Japan.

Clinical Case Reports
|October 2, 2025
PubMed

Insights

Heterozygous familial hypercholesterolemia (HeFH) requires early intervention to prevent cardiovascular disease. Combination therapy may be necessary for patients with a poor response to statins like pitavastatin.

Area of Science:

  • Cardiology
  • Genetics
  • Pediatrics

Background:

  • Familial hypercholesterolemia (HeFH) is a genetic disorder causing high cholesterol and early atherosclerosis.
  • HeFH significantly increases the risk of premature cardiovascular events, with over 60% mortality in untreated cases.
  • Early intervention in childhood is crucial for managing HeFH and preventing long-term complications.

Purpose of the Study:

  • To review the challenges and potential strategies for managing pediatric patients with HeFH.
  • To highlight the limitations of current treatment options in Japan, where only pitavastatin is approved for pediatric FH.
  • To explore the need for combination therapy in cases of suboptimal response to statins.

Main Methods:

  • Literature review on HeFH management in pediatric populations.
  • Analysis of treatment guidelines and approved medications for pediatric FH in Japan.
  • Discussion of therapeutic challenges and the potential role of combination therapy.

Main Results:

  • Pitavastatin is the sole statin approved for pediatric FH in Japan.
  • Some patients exhibit a poor response to statin monotherapy, complicating treatment efficacy.
  • Combination therapy is suggested as a potential approach for improving outcomes in non-responsive cases.

Conclusions:

  • Effective management of pediatric HeFH necessitates early and sustained intervention.
  • The limited availability of approved treatments in Japan poses a challenge for pediatric FH care.
  • Combination therapy warrants further investigation for optimizing lipid management in pediatric HeFH patients with poor statin response.

Keywords:
childezetimibefamilial hypercholesterolemiapitavastatin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.1K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
476
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246